Recent Updates
Recently added Catalysts
MLTX Negative Sentiment

MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & Squire, P.C. Urges Investors in MoonLake to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics (MLTX) on behalf of stockholders following a significant drop in stock value. On September 29, 2025, the company disclosed in an SEC filing that its VELA-2 trial did not achieve statistical significance due to unforeseen events in the placebo group, leading to an 89.9% decrease in stock price. The law firm is encouraging investors who suffered losses to contact them to discuss their legal options and rights.
Price reaction · baseline $9.1 (2025-10-08 close) · hit after-hours · clean, no other MLTX news in the window
day 0 close
+3.1%

Market Sentiment Analysis

CONCERNS & RISKS

  • MoonLake's stock plummeted 89.9% following a disappointing trial result.
  • The investigation suggests potential violations of federal securities laws.
  • The company is facing scrutiny regarding its business practices.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+83%
120-day peak, hindsight
Typical move
4.4%
average across 5 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
Sonelokimab
Phase 3 · Hidradenitis Suppurativa

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Moon Lake and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ:MLTX) on behalf of MoonLake stockholders. Our investigation concerns whether MoonLake has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On September 29, 2025, before the market opened, MoonLake Immunotherapeutics filed with the SEC a current report on Form 8-K. Attached to the current report was a press release which stated that, in MoonLake’s VELA-2 trial, “intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy[.]”
On this news, MoonLake stock plummeted 89.9% on September 29, 2025.
If you purchased or otherwise acquired MoonLake shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What is the purpose of the investigation into MoonLake?

Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake for possible violations of federal securities laws and unlawful business practices.

What happened to MoonLake stock on September 29, 2025?

On September 29, 2025, MoonLake stock dropped 89.9% after an announcement regarding their VELA-2 trial results.

How can I contact Bragar Eagel & Squire for assistance?

You can contact Brandon Walker or Marion Passmore at (212) 355-4648 or via email at investigations@bespc.com.

Is there a cost to get help from Bragar Eagel & Squire?

No, there is no cost or obligation for you to discuss your legal options with Bragar Eagel & Squire.

Where is Bragar Eagel & Squire located?

Bragar Eagel & Squire has offices in New York, South Carolina, and California.

Last updated: Oct 9, 2025